Plasma-treatment with the virucidal beta-propiolactone does not preclude analysis by large panel affinity proteomics, including the discovery of biomarker candidates https://www.medrxiv.org/content/10.1101/2023.06.29.23292027
Plasma-treatment with the virucidal beta-propiolactone does not preclude analysis by large panel affinity proteomics, including the discovery of biomarker candidates https://www.medrxiv.org/content/10.1101/2023.06.29.23292027